Sensi M, De Rossi M G, Celi F S, Cristina A, Rosati C, Perrett D, Andreani D, Di Mario U
Cattedra di Medicina Costituzionale ed Endocrinologia, Università degli Studi di Roma La Sapienza, Italy.
Diabetologia. 1993 Sep;36(9):797-801. doi: 10.1007/BF00400352.
D-Lysine, the non-physiological isomer of L-lysine, can competitively reduce protein non-enzymatic glycation in vitro. To study the effect of D-lysine in vivo, 6-8-week old Sprague-Dawley rats with streptozotocin-induced diabetes mellitus were treated from diagnosis for 45 days with two daily subcutaneous injections of D-lysine (0.5 g.ml-1.day-1). Another group of diabetic rats was only injected with equal volumes of physiological saline (0.9% NaCl). Glycated haemoglobin was measured by ion exchange chromatography, and glycated serum and lens proteins by boronate affinity gel chromatography. Serum and urinary creatinine concentrations were evaluated by the alkaline-picrate reaction. Urinary lysine concentrations at mid- and end-study were evaluated by cation exchange chromatography. Blood glucose concentrations, serum creatinine levels and creatinine clearances, measured at the end of the study, were similar in both diabetic groups (> 22.0 mmol/l, < or = 106 mumol/l and approximately 0.02 ml/s, respectively). Urinary lysine concentration in D-lysine-treated diabetic animals was more than 50-fold higher than in placebo-treated diabetic rats. In D-lysine-treated vs placebo-treated diabetic animals, a statistically significant reduction was found in the levels of glycated haemoglobin (stable HbA1; mean +/- SD = 3.00 +/- 0.74% vs 4.02 +/- 0.46%, p < 0.05; labile HbA1 = 3.92 +/- 0.89% vs 5.84 +/- 0.61%, p < 0.005), glycated serum proteins (1.40 +/- 0.47% vs 2.52 +/- 1.15%, p < 0.05) and glycated lens proteins (4.90 +/- 0.96% vs 5.98 +/- 0.65%, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
D-赖氨酸是L-赖氨酸的非生理性异构体，在体外可竞争性减少蛋白质非酶糖基化。为研究D-赖氨酸在体内的作用，对6至8周龄经链脲佐菌素诱导患糖尿病的斯普拉格-道利大鼠，自诊断起每日皮下注射两次D-赖氨酸（0.5 g·ml⁻¹·天⁻¹），持续治疗45天。另一组糖尿病大鼠仅注射等量生理盐水（0.9% NaCl）。采用离子交换色谱法测定糖化血红蛋白，用硼酸亲和凝胶色谱法测定糖化血清蛋白和晶状体蛋白。通过碱性苦味酸盐反应评估血清和尿肌酐浓度。研究中期和末期通过阳离子交换色谱法评估尿赖氨酸浓度。研究结束时测量的血糖浓度、血清肌酐水平和肌酐清除率在两组糖尿病大鼠中相似（分别> 22.0 mmol/l、≤ 106 μmol/l和约0.02 ml/s）。D-赖氨酸治疗的糖尿病动物尿赖氨酸浓度比安慰剂治疗的糖尿病大鼠高50多倍。与安慰剂治疗的糖尿病动物相比，D-赖氨酸治疗的糖尿病动物糖化血红蛋白水平（稳定的HbA1；平均值±标准差 = 3.00 ± 0.74% 对 4.02 ± 0.46%，p < 0.05；不稳定的HbA1 = 3.92 ± 0.89% 对 5.84 ± 0.61%，p < 0.005）、糖化血清蛋白水平（1.40 ± 0.47% 对 2.52 ± 1.15%，p < 0.05）和糖化晶状体蛋白水平（4.90 ± 0.96% 对 5.98 ± 0.65%，p < 0.05）有统计学显著降低。（摘要截断于250字）
